Spotlight On... ProMetic raises $30M; Novo Nordisk, AstraZeneca await study results; Lilly to showcase PhIII data; and more...

Canada's ProMetic Life Sciences has raised $30 million in debt financing from Structured Alpha LP, an affiliate of Peter J. Thomson's investment firm, Thomvest Asset Management. Thomson's investment firm has now invested $60 million in ProMetic. The biotech offers a range of services, including large-scale purification of biologics, drug development, proteomics and the elimination of pathogens. Release

@FierceBiotech: PTC: With no evidence of Duchenne MD efficacy, FDA barred regulators' doors to ataluren. Article | Follow @FierceBiotech

@JohnCFierce: Does Roche's IL-13 setback in PhIII signal similar trouble ahead for AstraZeneca? Story | Follow @JohnCFierce

@DamianFierce: Hillary Clinton: enemy of Gut Guy. Watch | Follow @DamianFierce

> Investors are carefully tracking two clinical studies at Novo Nordisk ($NVO) and AstraZeneca ($AZN) that are expected to read out soon. Story

> Eli Lilly ($LLY) plans to showcase new data on ixekizumab, its new drug for psoriatic arthritis and plaque psoriasis later in the week. Story

> Presidential candidate Hillary Clinton has dialed up her rhetoric on drug pricing, releasing a new ad that singles out Valeant Pharmaceuticals ($VRX) as a "predatory" company. Video

> AstraZeneca ($AZN) sold off the European rights to its opioid-induced constipation treatment, pocketing $70 million from Kyowa Hakko Kirin. News

Medical Device News

@FierceMedDev: Walgreens plots emergency exit from partnership with Theranos: FT. More | Follow @FierceMedDev

@EmilyWFierce: UPDATED: Zepatier beats Harvoni, Sovaldi in hep C clinical-data safety showdown: Advera Health Analytics. FiercePharma story | Follow @EmilyWFierce

> German startup Retina Implant nabs $28M for latest tech to restore sight to the blind. News

> Scientists create digital 'magic wand' to improve at-home device cybersecurity. Story

> Voice box maker Atos Medical goes on the chopping block for €1 billion: WSJ. Article

Pharma News

@FiercePharma: FDA swats down Teva's EpiPen copy, putting Mylan in cruise control. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Teva plots global rebrand as it prepares to join hands with Allergan's generics unit. Article | Follow @CarlyHFierce

> Big vials mean bigger revenue for cancer drugmakers, wasted billions for payers and patients. More

> Horizon Pharma joins Valeant in DOJ's specialty pharmacy probe. Story

> FDA swats down Teva's EpiPen copy, putting Mylan in cruise control. Article

Pharma Manufacturing News

> Lupin plans to add plant in Japan. News

> Potentially tainted heparin from China uncovered by French regulators. Report

> CMO helps TxCell move forward with clinical supplies after pilot plant closed. Item

> Novartis' Alcon unit recalls eye drop vials over questionable sterility. Story

> New plant to be online in UAE by end of 2016. Article

Pharma Asia News

> Bayer incoming CEO highlights OTC challenges in China in three-way integration. More

> China FDA prioritizes innovative drugs as 2015 approvals dipped. Story

> China's Mindray gets shareholder nod for reduced management-led buyout. Report

> China FDA chief Bi updates press on quality crackdown. More

> South Korea approved more clinical trials in 2015. Article

Drug Delivery News

> Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections. Item

> Sweden's Redwood gets private placement for its sustained-release dry eye disease candidate. Story

> AstraZeneca funds 'robotic pill' company Rani Therapeutics in pursuit of oral biologics. Article

> J&J, ViiV tout trial showing their long-acting HIV-fighting injectables are comparable to daily pills. More

> U.K.-Netherlands startups join forces for robot-assisted gene delivery to the eye. Article

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.